Farst Karen J, Valentine Jimmie L, Hall R Whit
Section for Children at Risk, Department of Pediatrics, University of Arkansas for Medical Sciences, 1 Children's Way, Slot 512-24A, Little Rock, AR 72202, USA.
Int J Pediatr. 2011;2011:951616. doi: 10.1155/2011/951616. Epub 2011 Jul 17.
Estimates of the prevalence of drug usage during pregnancy vary by region and survey tool used. Clinicians providing care to newborns should be equipped to recognize a newborn who has been exposed to illicit drugs during pregnancy by the effects the exposure might cause at the time of delivery and/or by drug testing of the newborn. The purpose of this paper is to provide an overview of the literature and assess the clinical role of drug testing in the newborn. Accurate recognition of a newborn whose mother has used illicit drugs in pregnancy cannot only impact decisions for healthcare in the nursery around the time of delivery, but can also provide a key opportunity to assess the mother for needed services. While drug use in pregnancy is not an independent predictor of the mother's ability to provide a safe and nurturing environment for her newborn, other issues that often cooccur in the life of a mother with a substance abuse disorder raise concerns for the safety of the discharge environment and should be assessed. Healthcare providers in these roles should advocate for unbiased and effective treatment services for affected families.
孕期药物使用流行率的估计因地区和所使用的调查工具而异。为新生儿提供护理的临床医生应具备识别在孕期接触过非法药物的新生儿的能力,可通过分娩时接触药物可能产生的影响和/或对新生儿进行药物检测来识别。本文的目的是概述相关文献,并评估药物检测在新生儿中的临床作用。准确识别其母亲在孕期使用过非法药物的新生儿,不仅会影响分娩前后新生儿护理的医疗决策,还能提供一个关键机会来评估母亲是否需要相关服务。虽然孕期药物使用并非母亲能否为新生儿提供安全和养育环境的独立预测因素,但有药物滥用障碍的母亲生活中经常出现的其他问题会引发对出院环境安全性的担忧,应予以评估。担任这些角色的医疗服务提供者应为受影响家庭倡导公正有效的治疗服务。